In 2020, the SEC issued new guidance on MD&A in light of COVID-19. The authors of this Securities & Commodities Regulation article discuss this guidance in detail, as well as recent amendments to Item 303 of Regulation S-K, and guidance on key performance indicators. They then turn to discussions of disclosure obligations relating to cybersecurity
Latest Post
More Posts
2021 SEC Filing Deadlines and Financial Statement Staleness Dates
Nasdaq Files Rule Proposal with SEC for Board Diversity and Disclosure Requirement
SEC Amends Shareholder Proposal Rule
SEC Amends Rule 14a-8
April 7 Webinar: COVID-19 Considerations for SEC Reporting Companies
Subscribe: Subscribe via RSS
Firm/Org